Americans Continue to Struggle to Access Branded GLP-1s as Shortages Continue
Hims & Hers Health (NYSE: HIMS) has revealed significant challenges in accessing branded GLP-1 medications across the US, with nearly 80,000 individuals on their platform reporting access difficulties. The company has launched a GLP-1 Supply Tracker to gather data on medication accessibility issues. In just one week, almost 7,000 individuals reported inability to access medications, particularly those containing semaglutide. In Texas, which ranks among the top 10 states for obesity rates, nearly 5,000 Hims & Hers customers reported access problems. Research shows that about 30% of Weight Loss customers previously prescribed branded GLP-1s couldn't fill their prescriptions due to unavailability.
Hims & Hers Health (NYSE: HIMS) ha rivelato importanti sfide nell'accesso ai farmaci GLP-1 di marca negli Stati Uniti, con quasi 80.000 persone sulla loro piattaforma che segnalano difficoltà di accesso. L'azienda ha lanciato un Tracker di Fornitura GLP-1 per raccogliere dati sui problemi di accessibilità dei farmaci. In appena una settimana, quasi 7.000 persone hanno riportato di non riuscire ad accedere ai medicamenti, in particolare a quelli contenenti semaglutide. In Texas, che figura tra i primi 10 stati per tassi di obesità, quasi 5.000 clienti di Hims & Hers hanno segnalato problemi di accesso. Le ricerche mostrano che circa il 30% dei clienti in cerca di perdita di peso precedentemente prescritti con GLP-1 di marca non è riuscito a ritirare le loro ricette a causa di indisponibilità.
Hims & Hers Health (NYSE: HIMS) ha revelado desafíos significativos para acceder a medicamentos GLP-1 de marca en los EE. UU., con casi de casi 80,000 personas en su plataforma reportando dificultades de acceso. La compañía ha lanzado un Rastreador de Suministro de GLP-1 para recopilar datos sobre problemas de accesibilidad de los medicamentos. En solo una semana, casi 7,000 personas informaron no poder acceder a medicamentos, especialmente aquellos que contienen semaglutida. En Texas, que se encuentra entre los 10 estados con las tasas de obesidad más altas, casi 5,000 clientes de Hims & Hers informaron problemas de acceso. La investigación muestra que aproximadamente el 30% de los clientes de Pérdida de Peso que fueron prescritos anteriormente con GLP-1 de marca no pudieron retirar sus recetas debido a la falta de disponibilidad.
Hims & Hers Health (NYSE: HIMS)는 미국 전역에서 브랜드 GLP-1 약물에 접근하는 데 심각한 문제를 드러냈습니다. 이 플랫폼의 거의 80,000명의 개인이 접근에 어려움을 겪고 있다고 보고했습니다. 이 회사는 약물 접근성 문제에 대한 데이터를 수집하기 위해 GLP-1 공급 추적기를 출시했습니다. 단 일주일 만에 거의 7,000명이 약물, 특히 세마글루타이드가 포함된 약물에 접근할 수 없다고 보고했습니다. 비만율이 높은 상위 10개 주 중 하나인 텍사스에서는 거의 5,000명의 Hims & Hers 고객이 접근 문제를 신고했습니다. 연구에 따르면, 브랜드 GLP-1이 이전에 처방된 체중 감량 고객의 약 30%가 공급 부족으로 처방전을 채울 수 없었습니다.
Hims & Hers Health (NYSE: HIMS) a révélé d'importants défis concernant l'accès aux médicaments GLP-1 de marque aux États-Unis, avec près de 80 000 personnes sur leur plateforme signalant des difficultés d'accès. L'entreprise a lancé un Suivi d'Approvisionnement GLP-1 pour recueillir des données sur les problèmes d'accessibilité des médicaments. En une semaine, près de 7 000 personnes ont signalé une incapacité à accéder aux médicaments, notamment ceux contenant du sémaglutide. Au Texas, qui figure parmi les 10 États ayant les taux d'obésité les plus élevés, près de 5 000 clients de Hims & Hers ont signalé des problèmes d'accès. Les recherches montrent qu'environ 30 % des clients en perte de poids précédemment prescrits avec des GLP-1 de marque n'ont pas pu obtenir leurs prescriptions en raison de l'indisponibilité.
Hims & Hers Health (NYSE: HIMS) hat erhebliche Herausforderungen beim Zugang zu markenpflichtigen GLP-1-Medikamenten in den USA offengelegt, wobei nahezu 80.000 Personen auf ihrer Plattform von Zugangsproblemen berichteten. Das Unternehmen hat einen GLP-1 Versorgungs-Tracker eingeführt, um Daten zu Problemen mit der Medikamentenverfügbarkeit zu sammeln. In nur einer Woche berichteten fast 7.000 Personen, dass sie keinen Zugang zu Medikamenten hatten, insbesondere zu solchen, die Semaglutid enthalten. In Texas, das zu den 10 Bundesstaaten mit den höchsten Fettleibigkeitsraten gehört, berichteten fast 5.000 Kunden von Hims & Hers über Zugangsschwierigkeiten. Forschungen zeigen, dass etwa 30 % der Kunden, die zuvor markenpflichtige GLP-1s verschrieben bekommen hatten, ihre Rezepte aufgrund von Nichtverfügbarkeit nicht einlösen konnten.
- Launch of GLP-1 Supply Tracker demonstrates proactive approach to addressing market needs
- Strong user engagement with 7,000 tracker submissions in first week
- Company leveraging data to communicate with regulatory agencies for improved healthcare access
- 80,000 customers unable to access branded GLP-1 medications
- 30% of Weight Loss customers unable to fill prescribed GLP-1 medications
- Supply shortage affecting company's ability to serve weight loss customers
Insights
The launch of Hims & Hers' GLP-1 Supply Tracker represents a strategic move to capitalize on the significant supply-demand gap in the GLP-1 market. With 80,000 individuals reporting access issues on their platform alone and a
- Strengthen relationships with regulatory bodies by providing valuable market intelligence
- Build brand authority in the weight loss space
- Potentially influence future supply allocations
- Demonstrate market leadership in addressing a critical healthcare access issue
The
Hims & Hers introduces a GLP-1 Supply Tracker to help more individuals advocate for accessible healthcare
Hims & Hers introduces a GLP-1 Supply Tracker to help more individuals advocate for accessible healthcare. (Graphic: Business Wire)
Hims & Hers has been collecting data on access challenges across GLP-1s since the beginning of September. On just the Hims & Hers platform alone, nearly 80,000 individuals have shared they cannot access branded GLP-1 medications. Those numbers are particularly pronounced in states where the obesity rate is higher. For instance, in
In an effort to better understand the access challenges across the US, Hims & Hers introduced the GLP-1 Supply Tracker to help more individuals share their experiences and use their voice to ensure the FDA has the information it needs to better support accessible care. In just one week, nearly 7,000 individuals have used the tracker to report that they cannot access their medications, with brand name products containing semaglutide reported as being the most challenging to access.
“Our customers have demonstrated a clear gap in supply and demand, so we’re making it easy for everyone to share their experience and be a part of advocating for better access to the medications they need,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “Part of our responsibility to the millions of customers who trust us with their healthcare is to understand the scale of the challenges they face and use our platform to combat them.”
Branded GLP-1 medications are challenging to access across the country, with availability fluctuating up and down as drugmakers invest in their ability to meet the immense amount of demand. While no official report has quantified the reach and impact of the shortage, research into Hims & Hers customers found that nearly
Consumers struggling to access the branded GLP-1 medications they’ve been prescribed can visit www.hims.com/weight-loss/supply-tracker or www.forhers.com/weight-loss/supply-tracker to share more about their experience.
About Hims & Hers Health, Inc
Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113063032/en/
Press Contact
Abby Reisinger
press@forhims.com
Source: Hims & Hers
FAQ
How many Hims & Hers (HIMS) customers reported inability to access GLP-1 medications?
What percentage of Hims & Hers (HIMS) Weight Loss customers couldn't fill their GLP-1 prescriptions?
How many people used Hims & Hers (HIMS) GLP-1 Supply Tracker in its first week?
